incretin semaglutide Diabetes Drug Molecule, Agonist. Skeletal Formula Stock Vector Semaglutide diabetes drug molecule (incretin

In addition, it can also help optimize future clinical trials

Researchers found that oral semaglutide decreased the risk of major cardiovascular events by 14% compared to placebo across age and gender

Important safety considerations include a boxed warning for thyroid C-cell tumors (these medications are contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2) and should not be used during pregnancy

The substantial weight loss these medications produce can include loss of lean muscle mass alongside fat, which has implications for long-term metabolic health and physical function